Peter M Glazer

List of Publications by Citations

184 papers	9,770 citations	56 h-index	93 g-index
195 ext. papers	10,985 ext. citations	8.4 avg, IF	6.18 L-index

#	Paper	IF	Citations
184	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. *Nature*, **2015**, 518, 107-10	50.4	591
183	MicroRNA regulation of DNA repair gene expression in hypoxic stress. *Cancer Research*, **2009**, 69, 1221-9	10.1	349
182	Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. *Molecular and Cellular Biology*, **2004**, 24, 8504-18	4.8	291
181	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. *Science Translational Medicine*, **2017**, 9,	17.5	283
180	Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. *Cancer Research*, **2005**, 65, 11597-604	10.1	269
179	Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. *Lancet, The*, **2002**, 359, 1471-7	40	251
178	Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. *Cancer Research*, **2008**, 68, 605-14	10.1	244
177	MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. *PLoS ONE*, **2010**, 5, e10345	3.7	243
176	Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. *Molecular and Cellular Biology*, **2003**, 23, 3265-73	4.8	231
175	Specific mutations induced by triplex-forming oligonucleotides in mice. *Science*, **2000**, 290, 530-3	33.3	228
174	Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2201-6	11.5	161
173	Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. *Radiotherapy and Oncology*, **2005**, 76, 168-76	5.3	156
172	Regulation of DNA repair in hypoxic cancer cells. *Cancer and Metastasis Reviews*, **2007**, 26, 249-60	9.6	153
171	Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. *Molecular Cancer Therapeutics*, **2012**, 11, 740-51	6.1	149
170	Targeted gene knockout mediated by triple helix forming oligonucleotides. *Nature Genetics*, **1998**, 20, 212-4	36.3	148
169	Hypoxic tumor microenvironment and cancer cell differentiation. *Current Molecular Medicine*, **2009**, 9, 425-34	2.5	128
168	Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2005**, 569, 75-85	3.3	121

167	Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. *Journal of Molecular Medicine*, **2007**, 85, 139-48	5.5	119
166	The potential for gene repair via triple helix formation. *Journal of Clinical Investigation*, **2003**, 112, 487-94	15.9	119
165	Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway. *Molecular and Cellular Biology*, **2000**, 20, 990-1000	4.8	115
164	Triplex-forming oligonucleotides: principles and applications. *Quarterly Reviews of Biophysics*, **2002**, 35, 89-107	7	114
163	In vivo correction of anaemia in β-thalassemic mice by PNA-mediated gene editing with nanoparticle delivery. *Nature Communications*, **2016**, 7, 13304	17.4	107
162	BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. *Journal of Clinical Oncology*, **1999**, 17, 3017-24	2.2	106
161	Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. *Molecular and Cellular Biology*, **2011**, 31, 3339-50	4.8	102
160	Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. *Cancer Biology and Therapy*, **2011**, 12, 908-14	4.6	100
159	Human XPA and RPA DNA repair proteins participate in specific recognition of triplex-induced helical distortions. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 5848-53	11.5	97
158	Interplay between DNA repair and inflammation, and the link to cancer. *Critical Reviews in Biochemistry and Molecular Biology*, **2014**, 49, 116-39	8.7	95
157	Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. *Nature Genetics*, **2018**, 50, 1086-1092	36.3	92
156	Mutagenesis induced by the tumor microenvironment. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1998**, 400, 439-46	3.3	92
155	Site-directed recombination via bifunctional PNA-DNA conjugates. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 16695-700	11.5	92
154	Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. *DNA Repair*, **2015**, 32, 180-189	4.3	89
153	Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. *Nucleic Acids Research*, **1999**, 27, 1176-81	20.1	89
152	Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. *Nature Communications*, **2015**, 6, 6952	17.4	88
151	In utero nanoparticle delivery for site-specific genome editing. *Nature Communications*, **2018**, 9, 2481	17.4	87
150	Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide. *Journal of Biological Chemistry*, **1999**, 274, 11541-8	5.4	83

149	Oncometabolites suppress DNA repair by disrupting local chromatin signalling. *Nature*, **2020**, 582, 586-591	50.4	82
148	Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. *Cancer Research*, **2005**, 65, 10734-41	10.1	81
147	HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutS *Molecular Cell*, **2014**, 55, 31-46	17.6	78
146	Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network. *Cancer Letters*, **2007**, 252, 93-103	9.9	78
145	Triplex-induced recombination in human cell-free extracts. Dependence on XPA and HsRad51. *Journal of Biological Chemistry*, **2001**, 276, 18018-23	5.4	78
144	Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 6134-9	11.5	76
143	Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 13514-9	11.5	75
142	Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. *Molecular Therapy*, **2011**, 19, 172-80	11.7	70
141	Emerging roles of microRNAs in the molecular responses to hypoxia. *Current Pharmaceutical Design* , **2009**, 15, 3861-6	3.3	70
140	Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. *Science Translational Medicine*, **2019**, 11,	17.5	69
139	microRNAs in cancer cell response to ionizing radiation. *Antioxidants and Redox Signaling*, **2014**, 21, 293-312	8.4	66
138	Chromosome targeting at short polypurine sites by cationic triplex-forming oligonucleotides. *Journal of Biological Chemistry*, **2001**, 276, 38536-41	5.4	64
137	The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells. *Breast Cancer Research*, **2018**, 20, 16	8.3	63
136	Gene targeting via triple-helix formation. *Progress in Molecular Biology and Translational Science*, **2001**, 67, 163-92		62
135	Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. *Annals of the New York Academy of Sciences*, **2005**, 1059, 184-95	6.5	61
134	Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities. *Yale Journal of Biology and Medicine*, **2017**, 90, 583-598	2.4	61
133	The cytotoxicity of (-)-lomaiviticin A arises from induction of double-strand breaks in DNA. *Nature Chemistry*, **2014**, 6, 504-10	17.6	60
132	Altered repair of targeted psoralen photoadducts in the context of an oligonucleotide-mediated triple helix. *Journal of Biological Chemistry*, **1995**, 270, 22595-601	5.4	60

131	Targeting cancer with a lupus autoantibody. *Science Translational Medicine*, **2012**, 4, 157ra142	17.5	59
130	Repair of DNA lesions associated with triplex-forming oligonucleotides. *Molecular Carcinogenesis*, **2009**, 48, 389-99	5	56
129	Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. *Journal of Clinical Investigation*, **2019**, 129, 5518-5536	15.9	56
128	Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formation. *Nucleic Acids Research*, **1994**, 22, 2845-52	20.1	54
127	Repair and recombination induced by triple helix DNA. *Frontiers in Bioscience - Landmark*, **2007**, 12, 4288-97	2.8	53
126	Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6. *Carcinogenesis*, **2006**, 27, 2402-8	4.6	53
125	Triplex formation by oligonucleotides containing 5-(1-propynyl)-2Rdeoxyuridine: decreased magnesium dependence and improved intracellular gene targeting. *Biochemistry*, **1999**, 38, 1893-901	3.2	53
124	Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing. *Molecules*, **2018**, 23,	4.8	51
123	Triplex-forming oligonucleotides as potential tools for modulation of gene expression. *Anti-Cancer Agents in Medicinal Chemistry*, **2005**, 5, 319-26		48
122	Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. *Cell Reports*, **2014**, 8, 501-13	10.6	46
121	Anti-tumor Activity of miniPEG-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy. *Molecular Therapy - Nucleic Acids*, **2017**, 9, 111-119	10.7	45
120	Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. *Chemistry and Biology*, **2011**, 18, 1189-98		45
119	High efficiency, restriction-deficient in vitro packaging extracts for bacteriophage lambda DNA using a new E.coli lysogen. *Nucleic Acids Research*, **1993**, 21, 3903-4	20.1	44
118	Targeted correction of a thalassemia-associated beta-globin mutation induced by pseudo-complementary peptide nucleic acids. *Nucleic Acids Research*, **2009**, 37, 3635-44	20.1	43
117	Molecular markers in clinical radiation oncology. *Oncogene*, **2003**, 22, 5915-25	9.2	43
116	Mcp1 Promotes Macrophage-Dependent Cyst Expansion in Autosomal Dominant Polycystic Kidney Disease. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 2471-2481	12.7	43
115	Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. *Breast Cancer Research and Treatment*, **2012**, 136, 67-75	4.4	41
114	Nanotechnology for delivery of peptide nucleic acids (PNAs). *Journal of Controlled Release*, **2016**, 240, 302-311	11.7	39

113	Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts. *Carcinogenesis*, **2000**, 21, 1291-1296	4.6	39
112	Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1. *Molecular Cancer Research*, **2018**, 16, 1458-1469	6.6	38
111	Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate. *Molecular Therapy*, **2012**, 20, 109-18	11.7	37
110	The tumor microenvironment and DNA repair. *Seminars in Radiation Oncology*, **2010**, 20, 282-7	5.5	37
109	Repair of DNA interstrand cross-links: interactions between homology-dependent and homology-independent pathways. *DNA Repair*, **2006**, 5, 566-74	4.3	37
108	Peptide conjugates for chromosomal gene targeting by triplex-forming oligonucleotides. *Nucleic Acids Research*, **2004**, 32, 6595-604	20.1	37
107	Functional and physical interaction between the mismatch repair and FA-BRCA pathways. *Human Molecular Genetics*, **2011**, 20, 4395-410	5.6	36
106	Single-stranded DNAs for in vivo site-specific genome editing via Watson-Crick recognition. *Current Gene Therapy*, **2014**, 14, 331-42	4.3	36
105	Triplex-induced recombination and repair in the pyrimidine motif. *Nucleic Acids Research*, **2005**, 33, 3492-502	20.1	35
104	Targeted genome modification via triple helix formation. *Annals of the New York Academy of Sciences*, **2005**, 1058, 151-61	6.5	35
103	Targeted cross-linking of the human beta-globin gene in living cells mediated by a triple helix forming oligonucleotide. *Biochemistry*, **2006**, 45, 1970-8	3.2	34
102	IGF1 receptor expression protects against microenvironmental stress found in the solid tumor. *Radiation Research*, **2002**, 158, 174-80	3.1	34
101	Mitochondrial DNA Stress Signalling Protects the Nuclear Genome. *Nature Metabolism*, **2019**, 1, 1209-1218	14.6	34
100	Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. *Breast Cancer Research*, **2010**, 12, 203	8.3	32
99	Site-directed gene mutation at mixed sequence targets by psoralen-conjugated pseudo-complementary peptide nucleic acids. *Nucleic Acids Research*, **2007**, 35, 7604-13	20.1	32
98	Induction of p53 in mouse cells decreases mutagenesis by UV radiation. *Carcinogenesis*, **1995**, 16, 2295-300	4.6	32
97	Modified poly(lactic-co-glycolic acid) nanoparticles for enhanced cellular uptake and gene editing in the lung. *Advanced Healthcare Materials*, **2015**, 4, 361-6	10.1	31
96	Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins. *Molecular Cancer Research*, **2014**, 12, 1016-28	6.6	31

95	Distance and affinity dependence of triplex-induced recombination. *Biochemistry*, **2005**, 44, 3856-64	3.2	31
94	Gene therapy for autosomal dominant disorders of keratin. *Journal of Investigative Dermatology Symposium Proceedings*, **2005**, 10, 47-61	1.1	31
93	Frequent spontaneous deletions at a shuttle vector locus in transgenic mice. *Mutagenesis*, **1996**, 11, 49-56	2.8	31
92	Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. *Cancer Research*, **2010**, 70, 409-17	10.1	30
91	Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites. *Cancer Biology and Therapy*, **2006**, 5, 1400-7	4.6	30
90	Triplex-stimulated intermolecular recombination at a single-copy genomic target. *Molecular Therapy*, **2006**, 14, 392-400	11.7	30
89	Site-specific gene modification by PNAs conjugated to psoralen. *Biochemistry*, **2006**, 45, 314-23	3.2	30
88	Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice. *Molecular Therapy - Nucleic Acids*, **2013**, 2, e135	10.7	29
87	Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. *International Journal of Radiation Oncology Biology Physics*, **2000**, 47, 1169-76	4	29
86	Src-Induced cisplatin resistance mediated by cell-to-cell communication. *Cancer Research*, **2009**, 69, 3619-24	10.1	28
85	Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. *Cancer Letters*, **2006**, 244, 195-202	9.9	28
84	Nanoparticle for delivery of antisense PNA oligomers targeting CCR5. *Artificial DNA, PNA & XNA*, **2013**, 4, 49-57		27
83	CHK2-dependent phosphorylation of BRCA1 in hypoxia. *Radiation Research*, **2006**, 166, 646-51	3.1	27
82	Transcription dependence of chromosomal gene targeting by triplex-forming oligonucleotides. *Journal of Biological Chemistry*, **2003**, 278, 3357-62	5.4	26
81	Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy **2000**, 88, 1091-1098		26
80	DNA-dependent targeting of cell nuclei by a lupus autoantibody. *Scientific Reports*, **2015**, 5, 12022	4.9	25
79	Activation of human gamma-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the gamma-globin gene 5′ flanking region. *Gene*, **2000**, 242, 219-28	3.8	25
78	Impact of hypoxia on DNA repair and genome integrity. *Mutagenesis*, **2020**, 35, 61-68	2.8	25

77	Nickel induces transcriptional down-regulation of DNA repair pathways in tumorigenic and non-tumorigenic lung cells. *Carcinogenesis*, **2017**, 38, 627-637	4.6	24
76	Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair. *Molecules*, **2020**, 25,	4.8	24
75	Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. *International Journal of Cancer*, **2000**, 90, 22-8	7.5	24
74	miR-155 Overexpression Promotes Genomic Instability by Reducing High-fidelity Polymerase Delta Expression and Activating Error-Prone DSB Repair. *Molecular Cancer Research*, **2016**, 14, 363-73	6.6	23
73	Optimizing biodegradable nanoparticle size for tissue-specific delivery. *Journal of Controlled Release*, **2019**, 314, 92-101	11.7	23
72	Tissue specificity of spontaneous point mutations in lambda supF transgenic mice. *Environmental and Molecular Mutagenesis*, **1996**, 28, 459-64	3.2	23
71	Triplex-mediated gene modification. *Methods in Molecular Biology*, **2008**, 435, 175-90	1.4	22
70	The NIH Somatic Cell Genome Editing program. *Nature*, **2021**, 592, 195-204	50.4	21
69	Frequent T:A-->G:C transversions in X-irradiated mouse cells. *Carcinogenesis*, **1995**, 16, 83-8	4.6	20
68	Targeted gene modification using triplex-forming oligonucleotides. *Methods in Molecular Biology*, **2004**, 262, 173-94	1.4	19
67	Triplex-mediated, in vitro targeting of psoralen photoadducts within the genome of a transgenic mouse. *Photochemistry and Photobiology*, **1996**, 63, 207-12	3.6	19
66	Hypoxia and DNA repair. *Yale Journal of Biology and Medicine*, **2013**, 86, 443-51	2.4	19
65	PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. *Molecular Cancer Research*, **2018**, 16, 1241-1254	6.6	18
64	Mutagenesis Mediated by Triple Helix-Forming Oligonucleotides Conjugated to Psoralen: Effects of Linker Arm Length and Sequence Context. *Photochemistry and Photobiology*, **1998**, 67, 289-294	3.6	17
63	Lambda phage shuttle vectors for analysis of mutations in mammalian cells in culture and in transgenic mice. *Mutation Research - Reviews in Genetic Toxicology*, **1989**, 220, 263-8		17
62	Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway. *Cancer Research*, **2020**, 80, 4655-4667	10.1	17
61	YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors. *Molecular Cancer Research*, **2015**, 13, 1389-97	6.6	16
60	Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. *Molecular Pharmacology*, **2011**, 80, 1000-12	4.3	16

59	Genomic instability in cancer. *Novartis Foundation Symposium*, **2001**, 240, 133-42; discussion 142-51		16
58	DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy. *Molecular Cancer Research*, **2017**, 15, 269-280	6.6	15
57	Targeted genome modification via triple helix formation. *Methods in Molecular Biology*, **2014**, 1176, 89-106	1.4	15
56	Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells. *Oncotarget*, **2019**, 10, 1272-1283	3.3	14
55	Polymer delivery systems for site-specific genome editing. *Journal of Controlled Release*, **2011**, 155, 312-6	11.7	14
54	Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in -deficient human renal cell carcinoma. *Oncotarget*, **2018**, 9, 4647-4660	3.3	14
53	Directed gene modification via triple helix formation. *Current Molecular Medicine*, **2001**, 1, 391-9	2.5	14
52	A cell-penetrating antibody inhibits human RAD51 via direct binding. *Nucleic Acids Research*, **2017**, 45, 11782-11799	20.1	13
51	Triplex-forming peptide nucleic acids induce heritable elevations in gamma-globin expression in hematopoietic progenitor cells. *Molecular Therapy*, **2013**, 21, 580-7	11.7	13
50	Development of a statewide hospital plan for radiologic emergencies. *International Journal of Radiation Oncology Biology Physics*, **2006**, 65, 16-24	4	13
49	Mechanism of action studies of lomaiviticin A and the monomeric lomaiviticin aglycon. Selective and potent activity toward DNA double-strand break repair-deficient cell lines. *Journal of the American Chemical Society*, **2015**, 137, 5741-7	16.4	12
48	LKB1 preserves genome integrity by stimulating BRCA1 expression. *Nucleic Acids Research*, **2015**, 43, 259-71	20.1	12
47	Electron-Mediated Aminyl and Iminyl Radicals from C5 Azido-Modified Pyrimidine Nucleosides Augment Radiation Damage to Cancer Cells. *Organic Letters*, **2018**, 20, 7400-7404	6.2	12
46	Clinical Efficacy of Olaparib in Mutant Mesenchymal Sarcomas.. *JCO Precision Oncology*, **2021**, 5, 466-472	3.6	11
45	Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors. *International Journal of Radiation Biology*, **2012**, 88, 277-85	2.9	10
44	Ku80-Targeted pH-Sensitive Peptide-PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing Radiation. *Molecular Cancer Research*, **2020**, 18, 873-882	6.6	9
43	Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides. *Cells*, **2021**, 10,	7.9	9
42	Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. *Cancer Research*, **2018**, 78, 6539-6548	10.1	9

41	MEN1 and FANCD2 mediate distinct mechanisms of DNA crosslink repair. *DNA Repair*, **2008**, 7, 476-86	4.3	8
40	Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide. *Molecular Pharmaceutics*, **2020**, 17, 461-471	5.6	8
39	Poly(Lactic-co-Glycolic Acid) Nanoparticle Delivery of Peptide Nucleic Acids In Vivo. *Methods in Molecular Biology*, **2020**, 2105, 261-281	1.4	8
38	Mlh1-dependent suppression of specific mutations induced in vivo by the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP). *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2006**, 594, 101-12	3.3	7
37	Oncogene expression in isogenic, EBV-positive and -negative Burkitt lymphoma cell lines. *Intervirology*, **1985**, 23, 82-9	2.5	7
36	Radiation sensitivity and sensitization in melanoma. *Pigment Cell and Melanoma Research*, **2013**, 26, 928-30	4.9	6
35	Tumor-targeted pH-low insertion peptide delivery of theranostic gadolinium nanoparticles for image-guided nanoparticle-enhanced radiation therapy. *Translational Oncology*, **2020**, 13, 100839	4.9	6
34	Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance. *Communications Biology*, **2021**, 4, 374	6.7	6
33	Debugging the genetic code: non-viral delivery of therapeutic genome editing technologies. *Current Opinion in Biomedical Engineering*, **2018**, 7, 24-32	4.4	6
32	Tumor suppressor p53 stole the AKT in hypoxia. *Journal of Clinical Investigation*, **2015**, 125, 2264-6	15.9	5
31	Therapeutic genome mutagenesis using synthetic donor DNA and triplex-forming molecules. *Methods in Molecular Biology*, **2015**, 1239, 39-73	1.4	5
30	Nanoparticles for delivery of agents to fetal lungs. *Acta Biomaterialia*, **2021**, 123, 346-353	10.8	5
29	Peptide nucleic acids and their role in gene regulation and editing. *Biopolymers*, **2021**, e23460	2.2	5
28	Targeted mutagenesis mediated by the triple helix formation. *Methods in Molecular Biology*, **1996**, 57, 109-18	1.4	4
27	Induction of aberrant crypt foci in DNA mismatch repair-deficient mice by the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP). *Cancer Letters*, **2006**, 244, 79-85	9.9	4
26	BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer. *British Journal of Pharmacology*, **2021**, 178, 3627-3647	8.6	4
25	Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities Report of an NCI Workshop held September 13, 2010. *Radiation Research*, **2011**, 176, e0016-e0021	3.1	3
24	Regulation of the Cell-Intrinsic DNA Damage Response by the Innate Immune Machinery. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3

23	Peptide nucleic acid-mediated recombination for targeted genomic repair and modification. *Methods in Molecular Biology*, **2014**, 1050, 207-22	1.4	3
22	High-throughput Evaluation of Protein Migration and Localization after Laser Micro-Irradiation. *Scientific Reports*, **2019**, 9, 3148	4.9	3
21	Triplex-mediated genome targeting and editing. *Methods in Molecular Biology*, **2014**, 1114, 115-42	1.4	2
20	New translational possibilities for microenvironmental modulation of radiosensitivity. *Radiation Research*, **2011**, 176, 412-4	3.1	2
19	Rec-A protein-mediated irreversible fixation of an oligodeoxyribonucleotide to specific site in DNA. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1996**, 351, 117-24	3.3	2
18	Abstract 6249: CBX-12: A low pH targeting alphalex□exatecan conjugate for the treatment of solid tumors **2020**,		2
17	Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts. *Carcinogenesis*, **2000**, 21, 1291-1296	4.6	2
16	Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity. *NAR Cancer*, **2021**, 3, zcab021	5.2	2
15	Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. *Oncologist*, **2021**, 26, e1104-e1109	5.7	2
14	Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. *Molecular Cancer Research*, **2021**, 19, 2057-2067	6.6	2
13	Genetic Instability Induced by Hypoxic Stress **2013**, 151-181		2
12	Pharmacological methods to transcriptionally modulate double-strand break DNA repair. *International Review of Cell and Molecular Biology*, **2020**, 354, 187-213	6	1
11	Peptide nucleic acids as agents to modify target gene expression and function. *International Journal of Peptide Research and Therapeutics*, **2003**, 10, 335-345	2.1	1
10	Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.. *Journal of Clinical Oncology*, **2019**, 37, e14664-e14664	2.2	1
9	Precise Genome Modification Using Triplex Forming Oligonucleotides and Peptide Nucleic Acids. *Advances in Experimental Medicine and Biology*, **2016**, 93-110	3.6	1
8	Genome Modification by Triplex-Forming Oligonucleotides. *Perspectives in Antisense Science*, **1999**, 167-179		1
7	Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010. *Radiation Research*, **2011**, 176, e0016-21	3.1	1
6	Regulation of DNA Repair by Hypoxia **2017**, 169-188		

5	Peptide nucleic acids as agents to modify target gene expression and function. *International Journal of Peptide Research and Therapeutics*, **2005**, 10, 335-345	2.1
4	Peptide nucleic acids as agents to modify target gene expression and function. *International Journal of Peptide Research and Therapeutics*, **2003**, 10, 335-345	
3	Targeted Genome Modification Via Triple Helix Formation **2004**, 27-43	
2	Genomic predictors of biochemical failure following radical prostatectomy.. *Journal of Clinical Oncology*, **2016**, 34, 114-114	2.2
1	Induction of a BRCAness state by oncometabolites and exploitation by PARP inhibitors.. *Journal of Clinical Oncology*, **2017**, 35, 11586-11586	2.2